Oncternal Therapeutics (ONCT) Peer Comparison

$0.53

$0.00 (0.00%)

As on 29-Apr-2025 09:30EDT

Market cap

$2 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

--

P/B Ratio

0.2

Div. Yield

0 %

Edit

	Oncternal Therapeutics (ONCT)	Aerovate Therapeutics Inc (AVTE)	Omega Therapeutics Inc (OMGA)
Market cap ($ Mln)	2	78	8
Revenue ($ Mln)	2	--	8
Net Profit ($ Mln)	-34.58	-48.96	-73.09
Net Margin (%)	-2,074.09	--	-902.93
RoE (%)	-215.60	-62.96	-276.36
Price to Earnings	--	--	--
Price-To-Book	0.17	35.57	0.23

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Oncternal Therapeutics (ONCT)	Aerovate Therapeutics Inc (AVTE)	Omega Therapeutics Inc (OMGA)
Operating Revenue	1.67	0.00	8.10
Cost of Revenue	18.63	0.10	12.94
Gross Profit	-28.97	-0.10	-62.78
Operating Expenses	37.63	81.41	78.65
Operating Profit (EBIT)	-35.96	-81.41	-74.15
Other Income	0.00	--	0.00
Profit before Tax	-34.58	-75.47	-73.09
Provision for Tax	-27.28	0.06	5.81
Profit after Tax (Net Income)	-34.58	-75.52	-73.09
Minority Interest	0.00	--	0.00
Consolidated Profit	0.00	--	0.00

Liabilities ($ Mln)

	Oncternal Therapeutics (ONCT)	Aerovate Therapeutics Inc (AVTE)	Omega Therapeutics Inc (OMGA)
Shareholder's Funds	9.15	109.46	11.54
Minority Interest	0.00	--	0.00
Non-Current Liabilities	0.00	0.33	117.01
Current Liabilities	6.45	17.64	24.17
Total Liabilities	36.73	127.42	204.37

Assets ($ Mln)

	Oncternal Therapeutics (ONCT)	Aerovate Therapeutics Inc (AVTE)	Omega Therapeutics Inc (OMGA)
Non-Current Assets	0.15	3.19	113.77
Current Assets	15.45	124.23	38.95
Total Assets	36.73	127.42	204.37
Total Debt*	0.19	0.68	128.13
Net Current Assets	8.99	106.60	14.78

Cashflow ($ Mln)

	Oncternal Therapeutics (ONCT)	Aerovate Therapeutics Inc (AVTE)	Omega Therapeutics Inc (OMGA)
Cash From Operating Activities	-32.16	-56.78	-91.51
Cash Flow from Investing Activities	--	--	--
Cash from Financing Activities	1.07	46.00	41.82
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Oncternal Therapeutics (ONCT)	Aerovate Therapeutics Inc (AVTE)	Omega Therapeutics Inc (OMGA)
ROCE (%)	61.76	-63.47	-61.86
ROE (%)	-215.60	-63.95	-276.36
ROA (%)	-98.22	-57.49	-34.68
EBIT Margin (%)	-3,246.13	--	-703.19
Net Margin (%)	-2,074.09	--	-902.93
Cash Profit Margin (%)	--	--	0.00

Growth Ratios

	Oncternal Therapeutics (ONCT)	Aerovate Therapeutics Inc (AVTE)	Omega Therapeutics Inc (OMGA)
Revenue Growth (%)	165.87	--	184.93
EBIT Growth (%)	-23.94	--	48.43
Net Profit Growth (%)	16.08	-46.61	31.48
EPS Growth (%)	17.49	--	--
Book Value Growth (%)	104.83	--	--

Valuation Ratios

	Oncternal Therapeutics (ONCT)	Aerovate Therapeutics Inc (AVTE)	Omega Therapeutics Inc (OMGA)
Price / Earnings	-0.04	--	--
Price / Book Value	0.05	--	--
Dividend Yield (%)	--	--	--
EV/EBITDA	-14.47	1.50	-0.59
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Oncternal Therapeutics (ONCT)	Aerovate Therapeutics Inc (AVTE)	Omega Therapeutics Inc (OMGA)
Debt to Equity	0.00	0.01	1.00
Short term debt to equity ratio	0.02	0.00	1.38
Current Ratio	2.39	7.04	1.61
Quick Ratio	2.39	--	1.61
Interest Coverage	-4,320.88	-30.40	-30.46

Operating Efficiency Ratios

	Oncternal Therapeutics (ONCT)	Aerovate Therapeutics Inc (AVTE)	Omega Therapeutics Inc (OMGA)
Debtors to sales (%)	20.64	--	6.00
Asset Turnover	0.05	0.00	0.04
Receivable days	188.44	--	518.48
Inventory Days	0.63	--	114.93
Payable days	24.95	9,456.55	13.11
Cash Conversion Cycle	164.12	--	620.31

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly